Deletions in variable region 1 of the HIV envelope accelerate V3-glycan bNAb induction in SHIV-infected rhesus macaques

Elicitation of broadly neutralizing antibodies (bNAbs) is a major goal of HIV-1 vaccine research. V3-glycan bNAbs were previously identified in a person living with HIV-1, CH848, and in two of six rhesus macaques (RMs) infected with a simian-HIV (SHIV) expressing the CH848 transmitted/founder envelope (Env) glycoprotein. In all cases, neutralization breadth developed after years of infection and only after the variable region 1 (V1) of Env had shortened in response to neutralizing antibodies. These observations suggested that V3-glycan bNAb elicitation might be accelerated if RMs were infected with SHIVs bearing CH848 Envs with truncated V1 loops. To test this hypothesis, we analyzed NAb responses in 10 RMs infected with SHIV.CH848 variants containing V1 deletions that mimicked those observed in natural infection. In three RMs, potent V3-glycan bNAbs developed within 1 y of infection, nearly three times faster than in wildtype CH848 infection. Longitudinal sequencing of B cell immunoglobulin genes revealed a single bNAb lineage in each RM that was primed as early as 8 to 12 wk postinfection and that largely recapitulated plasma breadth. A meta-analysis of the frequency of V3-glycan bNAb induction in RMs infected by SHIVs expressing CH848-derived Envs vs. 15 other primary HIV-1 Envs demonstrated a substantial enhancement in the CH848 group (5 of 16 vs. 2 of 109; P = 0.0003). We conclude that CH848 Envs have a propensity for inducing V3-glycan bNAbs and that truncations in their V1 loops accelerate precursor priming, findings that may guide HIV-1 vaccine design and inform current human vaccine trials.

Authors

Institutions

Publication Details

Journal
Proceedings of the National Academy of Sciences
Published
2026-09-29
DOI
https://doi.org/10.1073/pnas.2620354123
Primary Topic
HIV Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Deletions in variable region 1 of the HIV envelope accelerate V3-glycan bNAb induction in SHIV-infected rhesus macaques

Jinery Lora, Kasirajan Ayyanathan, George M. Shaw, Weimin Liu et al.
Proceedings of the National Academy of Sciences
HIV Research and Treatment
article

Deletions in variable region 1 of the HIV envelope accelerate V3-glycan bNAb induction in SHIV-infected rhesus macaques

Jinery Lora, Kasirajan Ayyanathan, George M. Shaw, Weimin Liu, Rumi Habib, Juliette M. Rando, Beatrice H. Hahn, John W. Carey, Barton F. Haynes, Ashwin N. Skelly, Katayoun Mansouri, Kevin J. Wiehe, Andrew Jesse Connell, Taylor N. Spence, Neha Chohan, Kevin O. Saunders, Chengyan Zhao, Michael S. Seaman, Wilton B. Williams, Kshitij Wagh, Ajay Singh, Shuyi Wang, Robert J. Edwards, Christian L. Martella, Michael P. Hogarty, Wenge Ding, Emily E. Lewis, Frédéric Bibollet‐Ruche, Macy J Akeley, Younghoon Park, Alexander Murphy, Hui Li
article en

Abstract

Elicitation of broadly neutralizing antibodies (bNAbs) is a major goal of HIV-1 vaccine research. V3-glycan bNAbs were previously identified in a person living with HIV-1, CH848, and in two of six rhesus macaques (RMs) infected with a simian-HIV (SHIV) expressing the CH848 transmitted/founder envelope (Env) glycoprotein. In all cases, neutralization breadth developed after years of infection and only after the variable region 1 (V1) of Env had shortened in response to neutralizing antibodies. These observations suggested that V3-glycan bNAb elicitation might be accelerated if RMs were infected with SHIVs bearing CH848 Envs with truncated V1 loops. To test this hypothesis, we analyzed NAb responses in 10 RMs infected with SHIV.CH848 variants containing V1 deletions that mimicked those observed in natural infection. In three RMs, potent V3-glycan bNAbs developed within 1 y of infection, nearly three times faster than in wildtype CH848 infection. Longitudinal sequencing of B cell immunoglobulin genes revealed a single bNAb lineage in each RM that was primed as early as 8 to 12 wk postinfection and that largely recapitulated plasma breadth. A meta-analysis of the frequency of V3-glycan bNAb induction in RMs infected by SHIVs expressing CH848-derived Envs vs. 15 other primary HIV-1 Envs demonstrated a substantial enhancement in the CH848 group (5 of 16 vs. 2 of 109; P = 0.0003). We conclude that CH848 Envs have a propensity for inducing V3-glycan bNAbs and that truncations in their V1 loops accelerate precursor priming, findings that may guide HIV-1 vaccine design and inform current human vaccine trials.

Proceedings of the National Academy of SciencesVol. 123(40)
Beth Israel Deaconess Medical Center (US), Duke University (US), Duke Medical Center (US), University of Pennsylvania (US)
Good health and well-being
Openalex Percentile: Top 13%
HIV Research and Treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.